-

Eurofins Opens Europe-Wide COVID-19 Testing Centre Network to Facilitate Summer Travel

LUXEMBOURG--(BUSINESS WIRE)--Easy, reliable, high-quality and cost-effective testing for SARS-CoV-2 (COVID-19), in compliance with local regulatory requirements, is crucial to enabling millions of passengers to complete their journeys in comfort and safety. Eurofins has rapidly developed a broad network of around 500 testing centres across Europe and intends to have established around 1000 testing centres by early July.

Eurofins’ network of testing centres covers major travelling hubs and provides testing accessibility in a broad variety of locations such as supermarkets, business parks and residential areas, improving customer proximity and ease of testing.

Eurofins also operates mobile testing centres to further increase availability and access. Such mobile facilities can be used by municipal authorities to reduce pressure on existing testing centres by quickly adding sampling capacity. These mobile collection centres can each process up to 200 PCR tests per day. Eurofins has already launched this service in Belgium, France and Germany.

Additionally, to further support testing, in particular for European travel this summer, Eurofins has created an intuitive web-portal for travelers to book testing appointments and access their testing information, not only in their country of origin, but also at destination locations. All of Eurofins’ testing centres are listed on a single landing page, identifying nearby testing locations. This portal is available in 12 languages; https://www.eurofins.com/covid19-travel-regulations-testing-stations/

Eurofins is committed to offering the best possible testing services to all travellers looking for a seamless, comfortable and safe travel experience. Eurofins has also invested in laboratory capacity and IT solutions that will ensure fast turn-around times for test results (as low as a few hours from receipt of sample at the laboratory for gold standard PCR Tests). Alongside Eurofins’ home-testing offering (where supported by Health Authorities), the Group’s extensive testing centres and mobile sample facilities enable Eurofins to offer an easy and comprehensive experience for international travellers across Europe and the world.

For more information, please visit https://www.eurofins.com/eurofins-safer-work-covid-19-solutions/.

Notes to editor:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Javier Sanchez Saura
Investor Relations
Eurofins Scientific SE
E-mail: ir@eurofins.com

Eurofins Scientific SE

BOURSE:ERF

Release Versions

Contacts

Javier Sanchez Saura
Investor Relations
Eurofins Scientific SE
E-mail: ir@eurofins.com

More News From Eurofins Scientific SE

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release. Financial highlights in FY 2025 Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spok...

Eurofins: Weekly Report on Share Repurchases From 19th January to 23rd January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/01/2026 FR0014000MR3 5 000 71.7101 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/01/2026 FR0014000MR3 5 000 70.5398 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 14/01/...

Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is excited to announce the development and launch of a new AI-powered software for high throughput salt and co-crystal screening – now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates. This breakthrough technolog...
Back to Newsroom